Skip to main content

Advertisement

Table 3 Body weight-adjusted rivaroxaban dosing schedule for children aged birth–< 18 years, as evaluated in EINSTEIN-Jra

From: Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study

Body weight (kg) Formulation od dose bid dose tid dose Total daily dose
Min Max
2.6 < 3 Oral suspension    0.8 mg 2.4 mg
3 < 4 Oral suspension    0.9 mg 2.7 mg
4 < 5 Oral suspension    1.4 mg 4.2 mg
5 < 6 Oral suspension    1.6 mg 4.8 mg
6 < 7 Oral suspension    1.6 mg 4.8 mg
7 < 8 Oral suspension    1.8 mg 5.4 mg
8 < 9 Oral suspension    2.4 mg 7.2 mg
9 < 10 Oral suspension    2.8 mg 8.4 mg
10 < 12 Oral suspension    3.0 mg 9 mg
12 < 20 Oral suspension   5 mg   10 mg
20 < 30 Tablet/oral suspension   5 mg   10 mg
30 < 50 Tablet/oral suspension 15 mg    15 mg
≥ 50 Tablet/oral suspension 20 mg    20 mg
  1. aDosing regimen, including dosing frequency, will be adjusted if the child’s body weight changes during the study. This dosing schedule may be subject to changes based on the results of the EINSTEIN-Jr phase III study; therefore, this dosing schedule cannot be used for the treatment of children with venous thrombosis outside the framework of the study
  2. bid twice-daily, od once-daily, tid three-times-daily